← Issue №16/ week of Oct 18, 2026/Hepatology

Effectiveness and safety of three years of bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: the Italian compassionate use program.

From GI Signals issue №16: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=97 · Oct 13, 2026 · Dig Liver Dis · IF 4.2

Effectiveness and safety of three years of bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: the Italian compassionate use program.

New evidenceviral hepatitiscirrhosishepatocellular carcinomabiomarker
Clinical takeawayConsider bulevirtide monotherapy (2 mg/day) for patients with HDV-related compensated cirrhosis, as it demonstrated sustained virological and biochemical responses with low rates of decompensation and HCC over 3 years.
What it foundBulevirtide monotherapy achieved 77% virological response, 84% biochemical response, and 64% combined response at 144 weeks, with 3-year cumulative probabilities of decompensation and HCC at 1.3% and 10%, respectively.
ContextThis real-world study confirms the long-term safety and efficacy of bulevirtide monotherapy in HDV-related cirrhosis, extending phase III trial findings and supporting its use in clinical practice.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Anolli MP … HEP4Di study group · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
← Read the whole of issue №16 Every paper GI Signals surfaces gets a page like this one. All issues